TrialClinical and translational science2024

Clinical pharmacokinetics and pharmacodynamics of ongericimab: A potential long-acting PCSK9 monoclonal antibody in healthy subjects and patients with hypercholesterolemia: Randomized, double-blind, placebo-controlled phase Ia and Ib/II studies.

Juanjuan Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.